These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 31140757)
1. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma. Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757 [TBL] [Abstract][Full Text] [Related]
2. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558 [No Abstract] [Full Text] [Related]
3. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma. Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523 [TBL] [Abstract][Full Text] [Related]
4. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma. Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110 [TBL] [Abstract][Full Text] [Related]
5. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
6. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma. Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903 [TBL] [Abstract][Full Text] [Related]
7. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma. Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612 [TBL] [Abstract][Full Text] [Related]
8. Immune and Clinical Features of Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752 [TBL] [Abstract][Full Text] [Related]
9. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Kristensen BW Neuropathol Appl Neurobiol; 2018 Feb; 44(2):185-206. PubMed ID: 28767130 [TBL] [Abstract][Full Text] [Related]
10. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients. Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935 [TBL] [Abstract][Full Text] [Related]
12. Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas. Liu X; Li Y; Sun Z; Li S; Wang K; Fan X; Liu Y; Wang L; Wang Y; Jiang T Cancer Med; 2018 Sep; 7(9):4273-4283. PubMed ID: 30117304 [TBL] [Abstract][Full Text] [Related]
13. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236 [TBL] [Abstract][Full Text] [Related]
15. Uridine phosphorylase 1 is a novel immune-related target and predicts worse survival in brain glioma. Wang J; Xu S; Lv W; Shi F; Mei S; Shan A; Xu J; Yang Y Cancer Med; 2020 Aug; 9(16):5940-5947. PubMed ID: 32583596 [TBL] [Abstract][Full Text] [Related]
16. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308 [TBL] [Abstract][Full Text] [Related]
17. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma. Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB Front Immunol; 2020; 11():606164. PubMed ID: 33408717 [TBL] [Abstract][Full Text] [Related]
18. RGS16 promotes glioma progression and serves as a prognostic factor. Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728 [TBL] [Abstract][Full Text] [Related]
19. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma. Qi Y; Chen D; Lu Q; Yao Y; Ji C Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736 [TBL] [Abstract][Full Text] [Related]
20. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker FAM111A in Diffuse Lower-Grade Glioma. Ji X; Ding F; Gao J; Huang X; Liu W; Wang Y; Liu Q; Xin T Front Oncol; 2020; 10():573800. PubMed ID: 33194678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]